PIA
IOVA icon

Piedmont Investment Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Piedmont Investment Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,427
Closed -$18K – 1647
2018
Q2 		$18K Buy
+1,427
New +$20.9K ﹤0.01% 1613

Other funds holding IOVA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Piedmont Investment Advisors's IOVA Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Iovance Biotherapeutics (IOVA) in Q3 2018, closing a stake of 1,427 shares — an estimated $18K sold.

Piedmont Investment Advisors first reported a position in IOVA in Q2 2018 and held it in 1 quarter. The position peaked at $18K in Q2 2018. 131 funds tracked by Wall St. Rank hold IOVA as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Iovance Biotherapeutics position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 1,427 Iovance Biotherapeutics shares in Q3 2018, an estimated $18K.
  • Piedmont Investment Advisors first reported a position in Iovance Biotherapeutics in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Iovance Biotherapeutics position peaked at $18K in Q2 2018.
  • 131 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.